SLC5A2 and Hepatic steatosis: For instance, we have reported that SGLT2 inhibitors; ipragliflozin and canagliflozin (CANA), improve hepatic steatosis in obese mice and delay the onset of nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma in a murine model of human NASH, in association with ‘healthy expansion’ of the adipose tissue [16,17].